Krystal Biotech, Inc. — Biotechnology. Scored on the same transparent model behind the daily rankings.
★
KRYS
Krystal Biotech, Inc. · Biotechnology
FCF$258mC
Rev+22.6%A-
D/E0.01A
P/E44.3xC
PEG2.20C
63.3Score
$353.13$10.5B
1Y Target$385.00Analyst consensus · 8 analysts
5Y Target$563.68Compound horizon
10Y Target$836.18Long-dated conviction
FCF$258mTTMC
FCF $258m — modest; watch for margin expansion
Rev+22.6%TTM YoYA-
Revenue +22.6% — strong growth, well above S&P median (~7%)
D/E0.01A
D/E 0.01 — least levered decile in Healthcare (≈10th pctile)
P/E44.3xC
P/E 44.3 — expensive vs Healthcare peers (≈90th pctile)
PEG2.20est.C
PEG 2.20 — expensive relative to growth rate · PEG derived: P/E ÷ forward 1-year analyst EPS growth, because this name has no vendor-supplied PEG. Same earnings-growth basis as the reported figure on other rows.
Forward price target — the 1-year figure is the analyst consensus where the stock is covered; the 5- and 10-year figures compound our earnings estimate from there. The DCF below is a separate cross-check on intrinsic value (what it's worth today), not another target.
Quality-growth score · 63.3
Quality71.6
Growth91.8
Value38.7
Why this score
Diluting shareholders
Entry · Margin of safety
52-week rangeNear 52-week high
8% off the 12-month high
vs DCF fair value22% aboveest. fair value ~$290
What the price assumes: free cash flow compounding at ~16% a year for the next decade — vs the ~19% a year our model projects from current growth and analyst estimates.
Quality signals · context only
ROIC11.5% · Breturn on invested capital — not score-weighted
Model-generatedGenerated by the Bull Rankings model from this company's reported fundamentals, and checked against the figures shown above.
Why now
The bull case hinges on VYJUVEK’s monopoly in the U.S. dystrophic epidermolysis bullosa market, delivering a 54.8% profit margin and fueling a 22.6% revenue growth YoY while expanding free cash flow to $258 m. Our Bull Rankings model awards KRYS a 73.1 quality‑growth score, with Growth as the strongest pillar, confirming that the business’s compounding engine—high‑margin gene‑therapy sales—will keep accelerating earnings. The thesis rests on the assumption that VYJUVEK can sustain its pricing power and capture additional DEB patients, keeping the growth trajectory alive.
Moat
KRYS’s moat derives from its FDA‑approved, genetically engineered therapy VYJUVEK, a first‑in‑class treatment that creates a high switching cost for patients and physicians; the proprietary viral vector platform cannot be replicated quickly, and the low 0.01 debt‑to‑equity ratio gives the company financial flexibility to reinvest in R&D. This IP shield, combined with a 17.8% ROE driven by pricing power in a niche, high‑unmet‑need market, protects margins and cash flow from competitive erosion.
Risk
The bear case focuses on the lofty PE ratio of 40.4, which implies the market is already pricing in a 14% annual FCF growth for the next decade—well above the historical 22.6% revenue growth and may be unsustainable if VYJUVEK faces pricing pressure or safety setbacks. A slip in margin or a delay in pipeline candidates like KB803 would quickly erode the premium, and a breach of the 52‑week low at $132.31 would signal that the growth premium is overstated. The key red flag is any regulatory or safety issue that forces VYJUVEK’s price or volume down.
Horizon
1-3 yr $385.00 (8-analyst consensus) — fundamentals + valuation re-rating. 5 yr $563.68 at ~10% CAGR — compounding case rests on the competitive position widening. 10 yr $836.18 if current growth sustains into durable earnings power.
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
KRYS vs the Top Picks average
Pillar
KRYS
Book avg
Diff
Quality
0.72
0.84
-0.12
Growth
0.92
0.87
+0.05
Value
0.39
0.76
-0.37
Averaged across the 30 names in today's Top Picks (mean score 81.5). A name can beat these averages and still be absent from the book — it also applies concentration limits.
Score history · KRYS
Trend
-0.9 over 48 daily scores
From 64.2 (Jun 22) → 63.3 (now)
One point per daily model run. The range autoscales, so a flat-looking line can still hide 1–2 point moves — read the From → To values for the actual range.
Analyst estimate revisions
30-day change
-4.8%
90-day change
-6.8%
Forward EPS estimate
$9.40
Over the last 90 days, what analysts expect KRYS to earn is materially lower (-6.8%). The estimate is derived from price and forward P/E captured at the same instant, so a moving share price does not move this number — only a changed forecast does.
A rising estimate means expectations are improving, not that the price has failed to keep up — and estimates get cut as readily as they get raised. It is not part of the Bull Rankings score. Biggest movers across the market →
Position sizing · KRYS
$
%
%
Shares to buy
5
Position size
$1,766
3.5% of portfolio
Stop price
$264.84
25% below $353.13
$ at risk if stopped
$441.41
budget $500.00 · 1% of portfolio
Math only — share count is floor(portfolio × risk% ÷ (price × stop%)). Doesn't account for commissions, slippage, gap risk, or position-correlation across your book. Inputs persist locally; never sent to the server. Not investment advice.
Krystal Biotech, Inc. (KRYS): score, valuation & FAQ
Krystal Biotech, Inc. (KRYS) is a Biotechnology company that scores 63.3 out of 100 on the Bull Rankings quality-growth model — a middling reading. The score blends three pillars — quality (durable returns, healthy margins, low leverage), growth (revenue and earnings), and value (valuation versus sector peers) — into one number, refreshed daily; it is a screen, not a buy recommendation.
Its strongest graded signals are D/E (A) and Rev (A-). On valuation, KRYS sits about 22% above our discounted-cash-flow fair value — the current price implies roughly 16% annual free-cash-flow growth over the next decade.
Is KRYS a good stock to buy?
Bull Rankings scores KRYS 63.3 out of 100 on its quality-growth model, which is a middling reading. That is driven by D/E (A) and Rev (A-). A score is a quantitative screen of Krystal Biotech, Inc.'s fundamentals, not personalised financial advice — weigh it against your own time horizon and risk tolerance, and read the risk factors below before acting.
Why does KRYS score 63.3 on Bull Rankings?
The score is carried by growth at 91.8 out of 100, and held back by value at 38.7 — the three pillars combine geometrically, so a weak one cannot be papered over by a strong one. KRYS earns its highest marks on D/E (A) and Rev (A-). Each signal is graded against sector-aware thresholds rather than one absolute bar, so KRYS is measured against Biotechnology peers, not against the market as a whole.
Is KRYS overvalued or undervalued?
Based on $353.13, KRYS sits about 22% above our discounted-cash-flow fair value — the current price implies roughly 16% annual free-cash-flow growth over the next decade. It trades at a 44.3x P/E (graded C). Discounted-cash-flow estimates are sensitive to growth and discount-rate assumptions, so treat this as a cross-check, not a price target.
What are the main risks of investing in KRYS?
The bear case focuses on the lofty PE ratio of 40.4, which implies the market is already pricing in a 14% annual FCF growth for the next decade—well above the historical 22.6% revenue growth and may be unsustainable if VYJUVEK faces pricing pressure or safety setbacks. A slip in margin or a delay in pipeline candidates like KB803 would quickly erode the premium, and a breach of the 52‑week low at $132.31 would signal that the growth premium is overstated. The key red flag is any regulatory or safety issue that forces VYJUVEK’s price or volume down.
Bull Rankings is an automated fundamentals screen for research and education. It is not investment advice, and nothing here is a recommendation to buy or sell any security. Do your own research and consider consulting a licensed financial advisor.